核心观点 - MDxHealth SA季度每股亏损0.16美元，较Zacks共识预期的每股亏损0.07美元差，盈利意外为-128.57% [1] - 公司季度营收2271万美元，较Zacks共识预期低20.31%，较上年同期的2743万美元下降 [2] - 公司年初至今股价下跌约95.9%，同期标普500上涨11.3% [3] - 公司当前Zacks评级为第3级（持有），预计近期股价表现与市场持平 [6] 盈利表现 - 季度每股亏损0.16美元，上年同期亦为每股亏损0.16美元，数据经非经常性项目调整 [1] - 上一季度预期每股亏损0.12美元，实际每股亏损0.18美元，盈利意外为-50% [1] - 过去四个季度公司均未能超越共识每股收益预期 [2] - 过去四个季度公司仅有一次超越共识营收预期 [2] 营收表现 - 截至2026年9月季度营收为2271万美元，较共识预期低20.31% [2] - 上年同期营收为2743万美元 [2] 股价与市场表现 - 公司股价年初至今下跌约95.9% [3] - 同期标普500上涨11.3% [3] 未来预期 - 下一季度共识每股收益预期为-0.08美元，营收预期为2970万美元 [7] - 当前财年共识每股收益预期为-0.49美元，营收预期为1.128亿美元 [7] - 财报发布前，公司盈利预期修正趋势为混合状态 [6] 行业情况 - 公司属于Zacks医疗信息系统行业，该行业当前在250多个Zacks行业中排名前24% [8] - 研究显示，Zacks排名前50%的行业表现超越后50%行业2倍以上 [8] 同业动态 - 同行业公司Phreesia（PHR）尚未公布截至2026年10月季度业绩，预计12月2日发布 [9] - Phreesia预计季度每股收益0.13美元，同比增长30%，共识每股收益预期过去30天保持不变 [9] - Phreesia预计营收1.2807亿美元，较上年同期增长6.4% [10]

MDxHealth (NasdaqCM:MDXH) Q3 2026 Earnings call November 12, 2026 04:30 PM ET Company ParticipantsJohn Fraunces - Managing DirectorMichael McGarrity - CEORon Kalfus - Interim CFOConference Call ParticipantsThomas Flaten - AnalystDan Brennan - AnalystMark Massaro - AnalystBill Bonello - AnalystOperatorPlease note this call is being recorded, and we are standing by if you should need any assistance. It is now my pleasure to turn the meeting over to John Fraunces with LifeSci Advisors. Please go ahead.John Fra ...

MDxHealth (NasdaqCM:MDXH) Q3 2026 Earnings call November 12, 2026 04:30 PM ET Speaker0Please note this call is being recorded, and we are standing by if you should need any assistance. It is now my pleasure to turn the meeting over to John Fraunces with LifeSci Advisors. Please go ahead.Speaker1Before we begin, I would like to remind everyone that the company will make forward-looking statements during today's call. Whether in prepared remarks or during the Q&A session, these forward-looking statements are ...

Conference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, Calif. – November 12, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced its financial results for the third quarter ended September 30, 2026. Michael K. McGarrity, CEO of mdxhealth, commented: “As we communicated in our October preliminary update, our third quarter results reflect a temporary disruption in our commercial execution due to accel ...